Postpartum Sexual Function in Pregnant Women With COVID-19
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04389489 |
Recruitment Status :
Recruiting
First Posted : May 15, 2020
Last Update Posted : September 2, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
COVID-19 Dyspareunia Postpartum Period |
Study Type : | Observational |
Estimated Enrollment : | 140 participants |
Observational Model: | Ecologic or Community |
Time Perspective: | Prospective |
Official Title: | Evaluation of Pregnant Women Diagnosed With COVID-19 Using Carol Postpartum Sexual Function and Dyspareunia Scale |
Actual Study Start Date : | May 14, 2020 |
Estimated Primary Completion Date : | September 25, 2020 |
Estimated Study Completion Date : | September 30, 2020 |

- Evaluation of pregnant women diagnosed with COVID-19 using Carol Postpartum Sexual Function and Dyspareunia Scale [ Time Frame: 3 months ]In the study planned to be carried out, it is aimed to identify women at risk of postpartum sexual dysfunction and dyspareunia early and benefit from the treatment and care services they need effectively.
- Evaluation of pregnant women diagnosed with COVID-19 using Carol Postpartum Sexual Function and Dyspareunia Scale [ Time Frame: 3 Months ]To reveal the difference in sexual life in postpartum period between healthy pregnant women and pregnant women diagnosed with COVID-19.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 45 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Pregnant Patient with COVID-19
Exclusion Criteria:
- Those with known sexual dysfunction disorder

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04389489
Contact: Merve Aldikactioglu Talmac, M.D. | +905325602366 | drmrve@hotmail.com |
Turkey | |
Kanuni Sultan Suleyman Training and Research Hospital | Recruiting |
Istanbul, Halkali, Turkey, 34307 | |
Contact: Merve Aldikactioglu Talmac, M.D. +905325602366 drmrve@hotmail.com |
Responsible Party: | Merve Aldikactioglu Talmac, MD, Specialist of Obstetrics and Gynecology, Kanuni Sultan Suleyman Training and Research Hospital |
ClinicalTrials.gov Identifier: | NCT04389489 |
Other Study ID Numbers: |
MTalmacCarol |
First Posted: | May 15, 2020 Key Record Dates |
Last Update Posted: | September 2, 2020 |
Last Verified: | August 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF) Clinical Study Report (CSR) Analytic Code |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Postpartum Period Dyspareunia COVID-19 |
Dyspareunia Sexual Dysfunction, Physiological Sexual Dysfunctions, Psychological Mental Disorders |